{
  "id": "5c72b4897c78d69471000071",
  "type": "summary",
  "question": "Describe the mechanism of action of Lurbinectedin.",
  "ideal_answer": "Lurbinectedin is a novel highly selective inhibitor of RNA polymerase II triggering caspase-dependent apoptosis of cancerous cells. It inhibits active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30240327",
    "http://www.ncbi.nlm.nih.gov/pubmed/29883879",
    "http://www.ncbi.nlm.nih.gov/pubmed/28683469",
    "http://www.ncbi.nlm.nih.gov/pubmed/30090974",
    "http://www.ncbi.nlm.nih.gov/pubmed/27630271",
    "http://www.ncbi.nlm.nih.gov/pubmed/30153704",
    "http://www.ncbi.nlm.nih.gov/pubmed/30362375"
  ],
  "snippets": [
    {
      "text": "Lurbinectedin is a novel highly selective inhibitor of RNA polymerase II triggering caspase-dependent apoptosis of cancerous cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29883879",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30153704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Lurbinectedin is an inhibitor of RNA polymerase II currently under clinical development for intravenous administration as a single agent and in combination with other anti-tumor agents for the treatment of several tumor types. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30090974",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30240327",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurbinectedin is an inhibitor of active transcription of protein-coding genes, causing DNA-break accumulation, apoptosis and modulation of the tumor microenvironment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30362375",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurbinectedin is structurally related to trabectedin and it inhibits active transcription and the DNA repair machinery in tumour cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683469",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27630271",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Lurbinectedin is a novel highly selective inhibitor of RNA polymerase II triggering caspase-dependent apoptosis of cancerous cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29883879",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}